603932 Disclosed is the use of a composition including degarelix in the manufacture of a medicament for delaying or preventing the progression of locally advanced prostate cancer to metastatic stage prostate cancer in a subject treated for prostate cancer identified as having prostate specific androgen (PSA) level of 20-50ng/mL, wherein the delaying or prevention is associated with reduced PSA failure rate.
